QLQing‐Shan Liu

Qing‐Shan Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qing‐Shan Liu has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Keqin Li

    Key Lab of Ministry of Education, National Research Center for Minority Medicine and Nutrition, Minzu University of China, Beijing, China

    1 shared publication
  • Shu‐Ran Li

    Key Lab of Ministry of Education, National Research Center for Minority Medicine and Nutrition, Minzu University of China, Beijing, China

    1 shared publication
  • Xiaoying Yin

    College of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, Shanghai, China

    1 shared publication
  • Xu Li

    Key Lab of Ministry of Education, National Research Center for Minority Medicine and Nutrition, Minzu University of China, Beijing, China

    1 shared publication
  • Zongran Pang

    School of Pharmacy, Minzu University of China, Beijing 100081, China

    1 shared publication

Latest Publications

  • Ellagic acid improves endogenous neural stem cells proliferation and neurorestoration through Wnt/β‐catenin signaling in vivo and in vitro

    by Qing‐Shan Liu, Shu‐Ran Li, Keqin Li, Xu Li, Xiaoying Yin, Zongran Pang

    To research the effects of the polyphenol ellagic acid (EA) on brain cells and to explore its mechanism of action, and to evaluate whether EA can be safely utilized by humans as a functional food or therapeutic agent. A photothrombosis-induced model of brain injury in rats was created, and EA was administered intragastrically to rats on 7 consecutive days post-venous ischemia. An oxygen-glucose deprivation and re-perfusion model was established in neural stem cells in order to research the effects on proliferation after 2 days of EA treatment in vitro. Administration of EA improved the rats’ nerve-related abilities, remedied infarct volumes and morphological changes in the brain, and enhanced the content of nestin protein in the brain semidarkness zone. The proliferation of NSCs and the expression of β-catenin and Cyclin D1 genes were also increased in primary cultured NSCs. EA administration can improve brain injury outcomes and increase the proliferation of NSCs through the Wnt/β-catenin signaling pathway. To the best of our knowledge, these results represent new insights on the mechanisms of the brain cell protective activity of EA. Thus, EA may be used in functional foods or medicines to help treat nerve dysfunction, neurodegenerative disease and aging. This article is protected by copyright. All rights reserved